Tue: Nice plunges on mixed TASE

The Tel Aviv Stock Exchange saw mixed performance. The Tel Aviv 35 Index rose 0.29%, while the Tel Aviv 125 and BlueTech Global Indices fell. Teva Pharmaceuticals (TEVA) gained 3.75% after strong Q3 results, while Nice (NICE) dropped 7.07% due to layoff plans. Turnover was NIS 4.61B in equities and NIS 4.87B in bonds.

Original reporting
Published Nov 3, 2026, 5:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 6:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tue: Nice plunges on mixed TASE — source image
Decision brief

The 30-second read

$NICEBearishMed
01

Why it matters

The only clearly actionable, company-specific catalyst with explicit detail is Nice’s 5% workforce layoff, which aligns with the largest single-name decline. Several other names are linked to Q3 results, but the article provides no figures, limiting conviction on the underlying drivers.

02

Market read

Traders can use the same-session catalysts to manage near-term positioning in the named movers, especially Nice’s restructuring headline.

03

What to watch

The article lacks the actual Q3 metrics and guidance for most companies, so traders should verify whether the declines were driven by revenue, margins, guidance, or one-off items before extending the move.

Relevance 6/10Novelty 5/10Timing: same-session Tel Aviv trading, with catalysts tied to Q3 results and a workforce layoff

Background

This is a Tel Aviv market wrap describing index performance, FX levels, and top movers, with several US-listed Israeli companies tied to Q3 results and one restructuring announcement.

Company-level read

Ticker impact

$NICEBearishMedium confidence
Context

Nice shares fell 7.07% after announcing it will lay off 5% of its workforce, making the restructuring a direct risk/sentiment catalyst.

Expected impact

Likely downside bias as the market prices restructuring risk and potential margin impacts.

Evidence & confidence

The article ties the largest single-name drop directly to the workforce reduction, a same-session catalyst that typically drives immediate repricing.

$TEVABullishMedium confidence
Context

Teva rose 3.75% on the Tel Aviv 35 Index after reporting strong third quarter results, indicating a positive earnings read-through.

Expected impact

Likely upward pressure as investors extrapolate improved fundamentals from the reported quarter.

Evidence & confidence

The article explicitly links the biggest gain to strong third-quarter results, a direct fundamental catalyst.

$ENLTBearishLow confidence
Context

Enlight Renewable Energy fell 2.13% after reporting its third quarter results, signaling the market reacted negatively to the quarter.

Expected impact

Likely continued weakness if investors focus on any underwhelming Q3 details.

Evidence & confidence

The article states the move and that it followed Q3 results, but provides no specific Q3 figures to confirm the reason for the negative reaction.

$NVMIBearishLow confidence
Context

Nova Ltd. fell 2.63% after reporting its third quarter results, indicating a negative earnings reaction.

Expected impact

Likely downside bias as the market digests the quarter’s implications.

Evidence & confidence

The article links the decline to Q3 results but omits the specific figures or guidance details needed for higher confidence.

$ICLBearishLow confidence
Context

ICL fell 4.06% in the Tel Aviv market wrap, with the article presenting it as part of the day’s biggest decliners.

Expected impact

Near-term downside pressure possible, but catalyst uncertainty limits conviction.

Evidence & confidence

ICL is named as a decliner, yet no specific news trigger is described in the text.

Market effects

Mixed earnings reactions across Israeli-listed tech/industrial names suggest selective risk appetite rather than a broad sector repricing.

Tel Aviv indices were mixed, implying idiosyncratic company catalysts dominated rather than a single macro driver.

Limited direct global spillover beyond sentiment for the specific US-listed Israeli tech/industrial names mentioned.

Counterpoint

The NICE layoff could be interpreted as proactive cost control that improves longer-term margins, so the initial selloff may be overdone without details on severance, savings, or demand outlook.

Key entities

  • Nice

    Announced it will lay off 5% of its workforce; shares fell 7.07%.

  • Teva Pharmaceutical Industries

    Reported strong third quarter results; shares rose 3.75%.

  • Enlight Renewable Energy

    Reported third quarter results; shares fell 2.13%.

  • Nova Ltd.

    Reported third quarter results; shares fell 2.63%.

Related articles

$TEVALow

Teva Settles Generic Drug Price-Fixing Case With 45 States

Teva Pharmaceutical Industries reached a preliminary settlement agreement with 45 states, Washington, D.C., and two U.S. territories over allegations of generic drug price-fixing. The terms, affected drugs, and pricing conditions are undisclosed. Teva faces claims of conspiring to inflate prices on 112 generic drugs, with some price hikes exceeding 1,000%. The case is ongoing, and no final agreement has been reached.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$CLDXMed

Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff

Celldex Therapeutics will halt development of barzolvolimab for eczema after Phase 2 trial failure, but plans approval filing for chronic hives. NChroma Bio will cut staff and explore strategic alternatives after halting hepatitis B drug testing. Isomorphic Labs partners with Merck for cancer drug development. Teva Pharmaceuticals' R&D chief is leaving, but analysts remain confident. VitriVax raised $87M for Lyme disease vaccine development.

$TEVALow

Teva Reaches Preliminary Settlement With 45 States and D.C. in Generic Drug Price-Fixing Case, Terms Undisclosed

Teva Pharmaceuticals reached a preliminary settlement with 45 states and D.C. over allegations of generic drug price-fixing, but financial terms and conditions remain undisclosed. The case involves claims that Teva and others coordinated price increases on generic drugs, with some hikes exceeding 1,000%. Teva has not admitted wrongdoing. Earlier settlements with other companies total over $566 million, with Sandoz agreeing to a $400 million deal in principle.